An Open-label Extension to Study 49653/461, to Assess the Long-term Safety of Rosiglitazone (Extended Release Tablets) in Subjects With Mild to Moderate Alzheimer's Disease.

Trial Profile

An Open-label Extension to Study 49653/461, to Assess the Long-term Safety of Rosiglitazone (Extended Release Tablets) in Subjects With Mild to Moderate Alzheimer's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 May 2017

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 31 Mar 2011 Additional trial investigator (Cheri Hudson) identified as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Actual patient number (33) added as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top